Type 2 diabetes (T2D) is more common than Type 1 diabetes (T1D) with about 90 to 95 percent of people with diabetes having T2D. According to the Centers for Disease Control and Prevention’s report, 30.3 million Americans, or 9.4% of the U.S. population have diabetes. More alarming, an estimated 84 million more American adults have prediabetes, which if not treated, will advance to diabetes within five years.
Read MorePrevention is key when it comes to bedsores. That’s how one long-term care facility in Halifax said it reduced the bedsore prevalence rate from 12 per cent to 1.9 per cent in six years. The wound care team at Northwood changed its focus from treating pressure injuries, commonly known as bedsores, to preventing them with a risk-assessment tool, monitoring and the use of a range of prevention products.
Read MoreKCI, an Acelity Company, today announced the launch of the V.A.C. VERAFLO CLEANSE CHOICE™ Large Dressing designed for use with V.A.C. VERAFLO™ Therapy to cleanse larger wounds with thick, fibrous exudate and infectious material such as slough, and may be used on patients when surgical debridement must be delayed or is not possible or appropriate.
Read MoreThough the human body has a tremendous capability to heal itself, the wound healing process can sometimes stall due to a variety of reasons such as ischemia, bacterial contamination and chronic inflammation.
Read MoreSANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce a partnership with HyperMed in Memphis, TN to sponsor a continuing clinical investigation on Diabetic Foot Ulcers (DFUs). This investigational work is expected to begin in August 2018.
Read MoreThe CMS will not continue an experiment that saved Medicare millions of dollars by reducing the use of non-emergency hyperbaric oxygen therapy. The treatment uses pressurized oxygen to help expedite wound healing, particularly for diabetic wound care. Since the CMS launched the experiment in 2015, its spending per beneficiary per quarter dropped by $60, according to a report released Monday by the CMS. Federal data shows the experiment saved the government $17.6 million by 2017.
Read MorePressure ulcers and the accompanying task of preserving residents’ skin integrity are never-ending challenges for long-term care providers. Not only is the treatment of pressure ulcers lengthy, it also costs an estimated $11 billion per year in the United States, with some $500 to $70,000 spent on each single wound.
Read MoreRedDress Ltd announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RD1 system. RD1 is an innovative wound care product which enables healthcare providers to produce in real time, in vitro whole blood clots, for use as a chronic wound care product. It has been developed to address the need for cost-effectiveness and clinical effectiveness of wound care.
Read MoreUsing microcurrent therapy along with traditional wound care approaches significantly reduces wound size and lessens pain, according to a study in the Journal of Wound Care. Harikrishna K.R. Nair, M.D., head of the wound care unit at Malaysia’s Hospital Kuala Lumpur, studied the effect of microcurrents on 100 chronic wound patients over four months in 2016. Their diagnoses included diabetic foot ulcers, venous leg ulcers and pressure ulcers.
Read MoreFormer Head of Vascular Surgery at Bradford’s Royal Infirmary Professor Peter Vowden gave the opening address at the 3rd International Skin Integrity and Tissue Viability Conference which explored advances in and the management of all aspects wound care.
Read More